15
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2030 |
Tiplaxtinin
PAI-039,Tiplasinin |
PAI-1; Apoptosis | Apoptosis; Metabolism |
Tiplaxtinin (Tiplasinin) 是一种具有口服活性的选择性纤溶酶原激活物抑制剂-1 抑制剂,IC50为 2.7 μM。 | |||
T8962 |
TM5007
|
PAI-1 | Metabolism |
TM5007 是纤溶酶原激活物抑制剂-1(PAI-1;IC50 为 29 uM)的强效抑制剂。 | |||
T4254 |
TM5441
|
PAI-1; Apoptosis | Apoptosis; Metabolism |
TM5441 是口服生物可利用的纤溶酶原激活物抑制剂-1 抑制剂,抑制多个癌症细胞系的 IC50值在 13.9 到 51.1 μM。它诱导几种人类癌症细胞的内在调亡,减弱 Nω-硝基-1-精氨酸甲酯诱导的心脏高血压和血管衰老。 | |||
T3442 |
UK-371804
UK371804 |
PAI-1; Serine Protease | Metabolism; Proteases/Proteasome |
UK-371804 是一种尿嘧啶型纤溶酶原激活物的抑制剂,Ki=10 nM。 | |||
T4255 |
TM5275 sodium
TM5275 sodium salt |
PAI-1 | Metabolism |
TM5275 sodium (TM5275 sodium salt) 是一种纤溶酶原激活物抑制剂,IC50=6.95 μM。 | |||
T13257 |
Upamostat
|
PAI-1; Serine/threonin kinase; Serine Protease | Cell Cycle/Checkpoint; Metabolism; Proteases/Proteasome |
Upamostat 是一种丝氨酸蛋白酶抑制剂,也是一种具有口服活性的 WX-UK1 前药,是一种尿激酶型纤溶酶原激活剂 (uPA) 抑制剂。 | |||
T13408 |
ZK824190
|
Others; Serine Protease | Others; Proteases/Proteasome |
ZK824190 是具有口服活性尿激酶型纤溶酶原激活剂 (uPA) 选择性抑制剂,对 uPA,tPA 和 Plasmin 的IC50分别为 237,1600 和 1850 nM。ZK824190在多发性硬化症中有研究价值。 | |||
T29856 |
Aleplasinin
PAZ 417,PAZ417,PAZ-417 |
PAI-1 | Metabolism |
Aleplasinin (PAZ 417) 是纤溶酶原激活物抑制剂 1 (PAI-1) 的选择性和口服活性抑制剂,是纤溶系统的关键负调节剂。 Aleplasinin 可用于阿尔茨海默病研究。 | |||
T28788 |
SK-216
SK216.Plasminogen activator inhibitor-1 (PAI-1) inhibitor |
||
SK-216 is a specific PAI-1 inhibitor. SK-216 reduced the extent of angiogenesis in the tumors and inhibited VEGF-induced migration and tube formation by human umbilical vein endothelial cells in vitro. SK-216 reduced the degree of bleomycin-induced pulmon | |||
T23764 |
AZ3976
AZ 3976,AZ-3976 |
PAI-1 | Metabolism |
AZ3976 是一种纤溶酶原激活物抑制剂-1抑制剂,在血浆凝块溶解试验中的 IC50为16μM。AZ3976 显示促纤维蛋白溶解活性。 | |||
T25915 |
Diaplasinin
PAI-749,PAI749,PAI 749 |
||
PAI-749 is a selective and effective antagonist agent of plasminogen activator inhibitor 1 (PAI-1). | |||
T68572 | IMD-1622 | ||
IMD-1622 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor. | |||
T25217 | CDE-096 | ||
CDE-096 is a plasminogenactivator inhibitor-1 (PAI-1) inactivator. | |||
T70810 |
THR-18
|
||
THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects. | |||
T35520 |
Aflatoxin G1-13C17
Aflatoxin G1-13C17 |
||
Aflatoxin G1-13C17is intended for use as an internal standard for the quantification of aflatoxin G1by GC- or LC-MS. Aflatoxin G1is a mycotoxin that has been found inA. terricola.1In vivo, aflatoxin G1is lethal to ducklings (LD50= 1.18 mg/kg).2It induces hepatocellular carcinoma tumor formation and lethality in rats when administered at doses of 1.4 and 3 mg/animal, respectively. Aflatoxin G1also inhibits liver and kidney succinate dehydrogenase and fumarase, as well as kidney cytochrome oxidase... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4S0592 |
Toddalolactone
(+)-Toddalolactone,飞龙掌血内酯,毛两面针素 |
PAI-1 | Metabolism |
Toddalolactone ((+)-Toddalolactone) 是一种Toddalia asiatica 的主要成分,能够抑制重组人纤溶酶原激活物抑制物-1(PAI-1)的活性, IC50=37.31 μM。 | |||
T3876 |
Loureirin B
龙血素B,龙血素 B |
PAI-1; ERK; Potassium Channel; JNK | MAPK; Membrane transporter/Ion channel; Metabolism |
Loureirin B 是从剑叶龙血树中分离到的一种黄酮,是 PAI-1抑制剂,IC50值为 26.10 μM。它抑制 KATP,以及 ERK 和 JNK 的磷酸化,具有抗糖尿病的功效。 |